title: Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
authors.affiliation: Medical Clinic III for Oncology, Haematology and Rheumatology, University Hospital Bonn, Bonn, Germany.
authors.forename: Annkristin
authors.initials: A
authors.lastname: Heine
authors.forename: Peter
authors.initials: P
authors.lastname: Brossart
authors.forename: Dominik
authors.initials: D
authors.lastname: Wolf
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000998:Antiviral Agents / Q000008:administration & dosage; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D017053:Infection Control / Q000379:methods; D053612:Janus Kinases / Q000037:antagonists & inhibitors; D009570:Nitriles; D055728:Primary Myelofibrosis / Q000188:drug therapy / Q000276:immunology; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011720:Pyrazoles / Q000009:adverse effects*; D011743:Pyrimidines; D012307:Risk Factors
chemical_list: D000900:Anti-Bacterial Agents; D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D009570:Nitriles; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib; D053612:Janus Kinases